Infections and Infectious Diseases | New Developments | FRANCE

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Sanofi to Enroll Thousands for its Coronavirus Vaccine Trials

Lead Product(s): COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 06, 2020

Details:

Sanofi is working on two vaccine projects to prevent COVID-19. Of more than 100 vaccine candidates in development, 10 have reached the clinical testing stage so far.

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Sanofi and Gsk to Join Forces in Unprecedented Vaccine Collaboration to Fight Covid-19

Lead Product(s): S-protein COVID-19 antigen

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: GlaxoSmithKline

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 14, 2020

Details:

Sanofi will contribute its S-protein COVID-19 antigen and GSK will contribute its proven pandemic adjuvant technology to the collaboration.

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Sanofi joins forces with U.S. Department of Health for COVID-19

Lead Product(s): SARS vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Biomedical Advanced Research and Development Authority

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration February 18, 2020

Details:

Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi’s well-established recombinant technology platform to expedite a potential COVID-19 vaccine.

Sanofi Pasteur SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19

Lead Product(s): mRNA vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Translate Bio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration March 27, 2020

Details:

Translate Bio will use its mRNA platform to discover, design, and manufacture a range of SARS-CoV-2 vaccines. Sanofi will provide deep expertise and support from its external research networks.

Valneva SE

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Batavia Biosciences to Partner with Valneva Sweden AB for Polio Vaccine Development

Lead Product(s): Inactivated polio vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Vaccine

Partner/Sponsor/Collaborator: Batavia Bioscience

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 16, 2020

Details:

Under the terms of the agreement, Valneva will manufacture the sIPV vaccine for clinical trial purposes in its state-of-the-art GMP polio manufacturing facility operated under GAPIII[2] polio containment in Solna, Sweden, using Batavia’s process.

Transgene

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Vaxxel Buys Transgene’s Cell Line to Develop New Vaccines

Lead Product(s): DuckCelt-T17

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Vaxxel

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition May 04, 2020

Details:

Vaxxel has acquired Transgene’s DuckCelt T17 cell line to develop industrial-scale vaccines against respiratory viruses.

Eusa Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

EUSA Pharma and Papa Giovanni XXIII Hospital, Italy, Provide Interim Analysis Data for Siltuximab-Treated COVID-19 Patients

Lead Product(s): Siltuximab

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 01, 2020

Details:

A third of patients with COVID-19 taking EUSA Pharma's interleukin (IL)-6 targeted monoclonal antibody siltuximab have experienced a clinical improvement, reveals a case-control trial in Italy.

MedinCell

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

MedinCell Receives $ 6.4 Million Grant From Unitaid to Fight Malaria

Lead Product(s): Ivermectin

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Unitaid

Deal Size: $6.4 million Upfront Cash: Undisclosed

Deal Type: Funding March 25, 2020

Details:

The grant aims to fund the formulation and preclinical activities of a 3-month acting injectable ivermectin to neutralize the transmission vector of Malaria.

Eusa Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

EUSA Pharma and Papa Giovanni XXIII Hospital to Initiate an Observational Case-control Study of Siltuximab in COVID-19

Lead Product(s): Siltuximab

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2020

Details:

The step was followed by the release of initial data from China suggesting a role of IL-6 in the development of Acute Respiratory Distress Syndrome as a result of COVID-19.

Antabio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Antabio Awarded $4.4 Million From CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fi...

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: CARB-X

Deal Size: $4.4 million Upfront Cash: Undisclosed

Deal Type: Funding January 02, 2020

Details:

The funding is to support the development of Antabio's novel small molecule candidate for the treatment of Pseudomonas aeruginosa infections in Cystic Fibrosis (CF) patients.

Find

Find Novel Drugs for Infections and Infectious Diseases under Development in FRANCE

France

Product Type

Companies

Sanofi

Sanofi to Enroll Thousands for its Coronavirus Vaccine Trials

Sanofi

Sanofi and Gsk to Join Forces in Unprecedented Vaccine Collaboration to Fight Covid-19

Sanofi

Sanofi joins forces with U.S. Department of Health for COVID-19

Sanofi Pasteur SA

Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19

Valneva SE

Batavia Biosciences to Partner with Valneva Sweden AB for Polio Vaccine Development

Transgene

Vaxxel Buys Transgene’s Cell Line to Develop New Vaccines

Eusa Pharma

EUSA Pharma and Papa Giovanni XXIII Hospital, Italy, Provide Interim Analysis Data for Siltuximab-Treated COVID-19 Patients

MedinCell

MedinCell Receives $ 6.4 Million Grant From Unitaid to Fight Malaria

Eusa Pharma

EUSA Pharma and Papa Giovanni XXIII Hospital to Initiate an Observational Case-control Study of Siltuximab in COVID-19

Antabio

Antabio Awarded $4.4 Million From CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fi...